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ABSTRACT  
Objectives. Neuritin 1 gene (NRN1) is involved in neurodevelopment processes and 
synaptic plasticity and its expression is regulated by Brain-Derived Neurotrophic Factor 
(BDNF). We aimed to investigate the association of NRN1 with schizophrenia-spectrum 
disorders (SSD) and bipolar disorders (BPD), to explore its role in age at onset and 
cognitive functioning, and to test the epistasis between NRN1 and BDNF.  
Methods. The study was developed in a sample of 954 SSD-BPD patients and 668 
healthy subjects. Genotyping analyses included eleven SNPs in NRN1 and one 
functional SNP in BDNF.   
Results. The frequency of the haplotype C-C (rs645649-rs582262) was significantly 
increased in patients compared to controls (p=0.0043), while the haplotype T-C-C-T-C-
A (rs3763180-rs10484320-rs4960155-rs9379002-rs9405890-rs1475157) was more 
frequent in controls (p=3.1x10
-5
). The variability at NRN1 was nominally related to 
changes in age at onset and to differences in intelligence quotient, in SSD patients. 
Epistasis between NRN1 and BDNF was significantly associated with the risk for 
SSD/BPD (p=0.005).   
Conclusions. Results suggest that: i) NRN1 variability is a shared risk factor for both 
SSD and BPD, ii) NRN1 may have a selective impact of on age at onset and intelligence 
in SSD, and iii) the role of NRN1 seem to be not independent of BDNF.  
 
KEYWORDS: schizophrenia-spectrum and bipolar disorders, NRN1, age at onset, 
intelligence, BDNF. 
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INTRODUCTION 
Schizophrenia and bipolar disorder are psychiatric disorders characterized by a 
prevalence of 2-3%, which increases up to 3.5% when other affective and non-
affective psychotic disorders such as schizoaffective or schizophreniform disorders are 
also included (Perala et al. 2007). A growing body of research suggests that 
schizophrenia-spectrum disorders (SSD) and bipolar disorder (BPD) share several 
epidemiological, clinical, neurobiological and genetic characteristics, raising important 
questions about the boundaries and distinctiveness of these psychiatric disorders.   
On the one hand, they have a number of symptoms in common particularly in acute 
episodes, with regard to the presence of psychotic symptoms; their age at onset is quite 
similar; and, although there must be neurochemical differences, several findings 
emphasise the likelihood of dopamine dysregulation in both (Murray et al. 2004).  
Available evidence also supports that a generalized deficit is present across SSD and 
BPD, even though quantitative differences may exist (Hill et al. 2013). In view of these 
similarities and taking into account that schizophrenic and affective symptoms do not 
have a taxonic structure, the integration of categorical and dimensional approaches has 
been suggested of particular interest to the complete understanding of psychotic 
disorders (Peralta and Cuesta 2007). 
On the other hand, an important genetic overlap between SSD and BPD has been 
classically reported by both epidemiological (Gottesman 1991; Lichtenstein et al. 2006) 
and molecular studies (Owen et al. 2007). More recently, the genome-wide approaches 
have evidenced a substantial shared polygenic contribution involving thousands of 
common genetic variants of small effect to the aetiology of these disorders (Lee et al. 
2013).  
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These shared genetic risk factors, along with the clinical and cognitive similarities, have 
led to the notion that these severe mental disorders can be placed in the same 
etiopathological continuum, probably representing different phenotypic manifestations 
of common underlying processes.  
 
In the search for specific genetic factors related to these disorders, studies face a number 
of challenges that arise from genetic and phenotypic complexity of these disorders. To 
this respect, it has been recently indicated that combining disorders with similar genetic 
risk profiles improves power to detect shared risk loci (Ruderfer et al. 2014). Similarly, 
the genotype-phenotype based approaches and the use of features with strong etiological 
significance have been suggested as a useful strategy to reduce heterogeneity and to 
identify specific genetic factors associated with such traits (Rasetti and Weinberger 
2011; Swerdlow et al. 2015).Then the observed variability on traits such as cognitive 
impairments and age at onset among patients may reflect differences in the distribution 
of etiological factors and possibly also differences underlying vulnerability. To this 
respect, heritability estimates indicate that genetic factors contribute significantly to age 
at onset of psychotic symptoms (Hare et al. 2010) and to general cognitive functioning 
(Deary et al. 2009). Moreover, cognitive impairments are present in 70% of the patients 
with schizophrenia (Palmer et al. 1997) and twin studies have shown that a large genetic 
overlap underlies the observed comorbidity between these two phenotypes 
(Toulopoulou et al. 2007; 2010). Also, the earlier forms of these disorders usually 
present severe clinical and cognitive expression, high incidence of treatment refraction 
and poor outcome (Rapoport et al. 2005; Joseph et al. 2008).  Accordingly, the 
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cognitive and clinical traits associated to age at onset may provide leads for recognizing 
and studying biological differences across diagnostic boundaries (Ongur et al. 2009). 
 
Linkage data have provided positional evidence implicating the short arm of 
chromosome 6 in the risk for SSD and also in their associated cognitive deficits (Straub 
et al. 1995; Schwab et al. 1995; Hallmayer et al. 2005). The most studied gene included 
in this chromosomal region is Dysbindin-1 gene (DTNBP1, 6p22.3), which has been 
consistently associated with SSD and BPD (Schwab and Wildenauer 2009) as well as 
with age at onset and cognitive deficits (Wessman et al. 2009; Fatjo-Vilas et al. 2011). 
Also in this region, and far less explored, there is the Neuritin 1 gene (NRN1, 6p25.1) 
also called candidate plasticity-related gene 15 (cpg15) (Nedivi et al. 1993). During 
early embryonic development, NRN1 is expressed in multiple brain regions and acts as a 
survival factor for neural progenitors and differentiated neurons (Putz et al. 2005). Later 
in development, NRN1 promotes growth and stabilization of axonal and dendritic arbors 
along with synapse formation and maturation (Cantallops et al. 2000; Javaherian and 
Cline 2005). NRN1 continues to be expressed in the adult brain, where its expression is 
correlated with activity-dependent functional synaptic plasticity (Corriveau et al. 1999; 
Harwell et al. 2005; Flavell and Greenberg 2008). Furthermore, the expression of NRN1 
is regulated by neurotrophins such as Brain-Derived Neurotrophic Factor (BDNF, 
11p13) (Naeve et al. 1997; Karamoysoyli et al. 2008). BDNF promotes the 
differentiation and growth of developing neurons in central and peripheral nervous 
systems (Buckley et al. 2007) and its intracellular distribution and activity-dependent 
secretion is altered by the Met variant of a functional polymorphism in the BDNF gene, 
which consists of a valine (Val) substitution for methionine (Met) at codon 66 
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(Val66Met).  Interestingly, BDNF gene polymorphisms have been associated with 
clinical symptoms –such as age at onset- and cognitive functioning in both SSD and 
BPD (Krebs et al. 2000; Rybakowski et al. 2006). 
According to all the above mentioned, NRN1 was already considered a candidate gene 
for neurodevelopment disorders by Chandler et al. (2010), who reported the effect of 
NRN1 polymorphic variation on general intelligence impairments in patients with 
schizophrenia. We considered the interest of investigating the implication of NRN1 in 
the aetiology not only of schizophrenia, but also across the schizophrenia-spectrum and 
bipolar disorder continuum. Moreover, we also aimed to extend the previous study on 
the relationship of NRN1 with cognitive impairments by testing the effect of this gene 
on age at onset, a characteristic that is related to cognitive performance. 
As synaptic plasticity alterations have been suggested to be present both in SSD and 
BPD (Craddock et al. 2006), we hypothesized that sequence variability of the gene 
would be related to the risk for developing any of these disorders. Considering the 
described involvement of NRN1 in cognitive processes, we also hypothesized that 
NRN1 gene could exert its effect not only by modulating general cognitive functioning, 
but also age at onset. Finally, given that NRN1 is a BDNF-regulated gene, we explored 
the statistical epistasis between NRN1 and BDNF as a proxy analysis of their 
involvement in common biological pathways.  
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MATERIALS AND METHODS 
Sample 
The patients’ sample comprised 954 individuals of Spanish Caucasian origin. They 
were drawn from consecutive admissions to three Child and Adolescent Psychiatry 
Units and four Adult Psychiatric Units, and were evaluated by experienced 
psychiatrists. All of them met the DSM-IV-TR diagnosis criteria: 73% schizophrenia-
spectrum disorders (49% schizophrenia, 11% schizophreniform disorder, 8% 
schizoaffective disorder, 5% Psychotic Disorder NOS) and 27% bipolar disorder I or II. 
Exclusion criteria included: age above 65 years, major medical illnesses that could 
affect brain functions, substance-induced psychotic disorder, neurological conditions, 
history of head trauma with loss of consciousness and having at least one parent not 
from Spanish Caucasian origin. Patients were diagnosed based on the following 
schedules: KSADS (Kaufman et al. 1997) for patients up to 17 years of age, and SCID 
(First et al. 1997) or CASH (Andreasen et al. 1992) for adult patients. Age at onset of 
the first episode was determined by means of these clinical schedules and/or the SOS 
inventory (Perkins et al. 2000). 
The control sample consisted of 668 Spanish Caucasian unrelated adult healthy 
individuals. They met the same exclusion criteria as patients. They were recruited from 
university students and staff, and their acquaintances, plus independent sources in the 
community. They were interviewed and excluded if they reported a history of mental 
illness and/or treatment with psychotropic medication.  
All participants provided written consent after being informed about the study 
procedures and implications. In the case of patients below the age of 18, written 
informed consent was also obtained from their parents or legal guardians. The study 
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was performed in accordance with the guidelines of the institutions involved and was 
approved by the local ethics committee of each participating centre. All procedures 
were carried out according to the Declaration of Helsinki. 
 
Neurocognitive assessment 
The general cognitive performance was evaluated in 607 patients and in 476 healthy 
subjects. Intellectual quotient (IQ) was estimated using the Block Design and 
Vocabulary or Information subtests of the WAIS-III (Wechsler 1997) or WISC-IV 
(Wechsler 2004), in accordance with the method suggested by Sattler (2001). Cognitive 
assessment was carried out by experienced neuropsychologists. In patients, the 
cognitive evaluation was conducted when stabilization of symptoms and readiness for 
cognitive evaluation was decided by the clinical team. 
 
Molecular Analyses  
Genomic DNA was extracted from peripheral blood cells or from buccal mucosa using 
standard methods: the Real Extraction DNA Kit (Durviz S.L.U., Valencia, Spain) or the 
BuccalAmp DNA Extraction Kit (Epicentre® Biotechnologies, Madison, WI).  
Coverage of NRN1 genomic sequence and 10kb upstream and downstream was 
achieved by including 11 tag SNPs (Table 1). The optimal set of SNPs that contained 
maximum information about surrounding variants was selected by using SYSNPs 
(http://www.sysnps.org/) with a minor allele frequency (MAF) >5 %, using pairwise 
option tagger (threshold of r
2
= 0.8). The SNPs included in Chandler et al study were 
also considered. The SNP rs6265 (Val66Met) at BDNF gene was also genotyped. 
Genotyping was performed using a fluorescence-based allelic discrimination procedure 
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(Applied Biosystems Taqman 5’-exonuclease assays). Standard conditions were used. 
The genotyping call rate for all SNPs was higher than 94.2% and all were in Hardy-
Weinberg equilibrium. 
TABLE 1  
Statistical analyses 
All data were processed using SPSS 21.0 software (SPSS IBM, New York, U.S.A). The 
program Haploview v4.1 (Barrett et al. 2005) was used to estimate the Hardy-Weinberg 
equilibrium and the linkage disequilibrium (LD) between NRN1 SNPs (Figure S1 in 
Supplementary Material). By means of using the Solid Spine criteria three haplotype 
blocks were identified (Block 1: SNP1-SNP3, Block 2: SNP4-SNP5 and Block 3: 
SNP6-SNP11) and a sliding window analysis was conducted within each block. 
The genetic power was calculated using Epi-info-v3.5.1 (Dean et al. 1991) by assuming 
an additive model, a disease prevalence of 3% and minor allele frequencies in 
accordance with those observed in sample. All markers had an 80% power to detect a 
genetic effect with an OR≥1.2.   
Case-control associations were analysed using the Unphased-v3.1.4 (Dudbridge 2003), 
using a cut-off threshold for rare haplotypes of 1%. A 10000 permutations procedure 
was applied to all tests to limit type II error. The odds ratios (OR) were estimated from 
the absolute number of alleles/haplotypes estimated in patients and controls (EpiInfo-
v3.5.1).  
Additive models as implemented in Plink 1.07 (Purcell et al. 2007) were used to 
conduct lineal regression analyses to explore the relationship between NRN1 and age at 
onset and IQ. First, the relationship between the NRN1 and age at onset was tested in 
the complete patients’ sample (including gender and diagnosis group as covariates) and 
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also separately in each group (adjusted by gender). Second, the relationship between the 
NRN1 and IQ was tested in the complete patient’s sample (including age at onset, 
months of evolution and diagnosis group as covariates) and also separately in SSD, 
BPD (adjusted for age at onset and months of evolution) and controls. PLINK’s max(T) 
permutation procedure with 10000 iterations was performed.  
The effect of NRN1 and BDNF interaction was tested both on: i) the risk for developing 
SSD or BPD, ii) age at onset (adjusted for sex and diagnosis) and IQ (adjusted for age at 
onset and months of evolution), in patients. Epistasis was explored using the model 
based multifactor dimensionality reduction (MB-MDR) approach by applying ‘mbmdr’ 
R-package (Calle et al. 2010). This method merges multi-locus genotypes in order to 
overcome the dimensionality problem and to increase the power to detect gene 
interactions associated with disease or phenotype. It also allows adjusting for 
confounding effects and correcting for multiple testing by 1000 permutations approach. 
In all analyses, the significance cut-off was established at p-value of 0.05.  
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RESULTS 
Sample characteristics  
Table 2 shows the main sociodemographic and clinical data of the sample. Variables 
that showed differences between groups were used as covariates when appropriate (see 
statistical analyses section). 
TABLE 2  
 
Association analysis of NRN1 and schizophrenia-spectrum and bipolar disorders 
There were no differences between sampling groups as regards the genotypic 
distribution of each polymorphism (data not shown), and genotype frequencies showed 
no gender differences within groups (patients and controls; data not shown).  
SNP1 (G allele), SNP4 (C allele) and SNP5 (C allele) were significantly more frequent 
among patients compared to controls (2=4.81 p=0.028, 2=5.05 p=0.024 and 2=8.04 
p=0.004, respectively). After multiple correction adjustment only the association of 
SNP5 remained significant (OR(95%CI)=1.27(1.07-1.49), empirical p-value=0.044)). 
Haplotypes associated with SSD and BPD are given in Table 3. The frequency of the 
haplotype G-C (Block 1: SNP1-SNP2) and haplotype C-C (Block 2: SNP4-SNP5) was 
significantly increased in patients than in controls. The result in Block 2 remained 
significant after permutation procedure; then, this haplotype was considered a risk 
haplotype for SSD and BPD. On the contrary, the haplotype T-C-C-T-C-A (Block 3: 
SNP6-SNP11) had higher frequencies in controls. Results in Block 3 also remained 
significant after multiple testing and could be considered as reflecting a protective effect 
of this haplotype. Note that other haplotypes included in the haplotype in Block 3 were 
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also detected (Table S1 in Supplementary Material). These results remained essentially 
unchanged when only SSD patients and controls were included.   
 
TABLE 3  
 
NRN1 and age at onset of the disorders 
Patients carrying two copies of the T allele at SNP2 (15.33%) presented a lower age at 
onset than those not carrying this allele (=-0.772 p=0.029). Patients homozygous for 
the C allele of SNP10 (7.80%) also showed later age at onset than those not carrying 
this allele (=0.918 p=0.016). The haplotype C-A (SNP10-11) was associated with age 
at onset: (=0.956 p=0.015) and also several haplotypes within Block 3 (all including 
the C-A haplotype) (Table S2 in Supplementary Material).  
When the same analysis was conducted only including SSD patients, the results for 
SNP10 and haplotype SNP10-11 remained significant while SNP2 did not (Table S3 in 
Supplementary Material). In an additive way, carrying two copies of the haplotype C-A 
was associated with later SSD age at onset (Figure 1A).  However, these results were 
not significant after permutation procedure. No association was detected within BPD 
patients’ group.  
 
NRN1 and cognitive functioning 
In SSD patients, the same haplotypes within Block 3 contributed to IQ scores (Table S4 
in Supplementary Material). A linear trend was detected between the number of copies 
of these haplotypes and higher IQ scores (Figure 1B), meaning that subjects carrying 
these haplotypes showed better general cognitive performance than non-carrier subjects. 
However, after permutation analyses these results did not remain significant. No 
  13 
 
significant association with IQ was detected between these polymorphisms either in the 
whole patients’ sample, in BPD or in healthy subjects.  
 
FIGURE 1 
 
Epistasis between NRN1 and BDNF 
Two order gene-gene interaction models were developed and revealed the effect of the 
BDNF Val/Val genotype in combination with different NRN1 variants (SNP1 (GG: 
=0.654 p=0.001), SNP3 (AA: =0.514 p=0.003) and SNP9 (TG: =0.457 p=0.0004)) 
on an increased risk for developing both SSD and BPD. In contrast, BDNF Met/Met 
was associated with a lower risk in combination with NRN1 SNP2 (TT: =-2.185 
p=0.0052). After permutation analysis, the interaction BDNFxNRN1SNP9 remained 
significant (p=0.005).  No significant epistatic effect was detected on age at onset and 
IQ after permutation. 
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DISCUSSION   
This case-control based approach adds to the only one previous Neuritin 1 gene 
association study developed by Chandler et al. (2010) in a sample of 336 patients with 
schizophrenia and 172 controls. Unlike Chandler and collaborators, in our sample of 
954 patients and 668 healthy subjects we report that NRN1 sequence variability 
accounts for a modest proportion of the risk for these disorders. On the one hand, we 
have identified a two SNP haplotype (SNP4-SNP5: C-C) that is associated with the risk 
for these disorders. As expected, due to the polygenic architecture of the studied 
disorders, the effect of this haplotype is small although significant (OR=1.28). On the 
other hand, we have observed haplotypes in the 5’ upstream region that have a 
protective effect. Although significance for these associations persisted after 
permutation procedure, the low frequency of the protective haplotypes in the population 
has to be considered when evaluating the attributable risk associated to these genetic 
variants.  
 
The present study also provides new evidence of interest as regards understanding the 
heterogeneity in age at onset and cognitive performance of SSD and BPD. Our results 
suggest that NRN1 variability has a role in SSD age at onset, pointing towards a specific 
effect on modifying neurodevelopment processes related to the time of emergence of 
these disorders. Although these results should be interpreted cautiously because they are 
only significant at an uncorrected level, it is interesting that the C allele of SNP10, 
which is included in the above described protective haplotype, is associated with a later 
age at onset of SDD. Then, taking into account that the 51% of SSD patients are carriers 
of this allele (358 C carriers vs 339 TT), together with the particularly poor prognosis 
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associated to schizophrenia in childhood and adolescence in contrast to the adult 
manifestation (Clemmensen et al. 2012), this modulatory effect is of non-dismissible 
potential clinical interest. 
Our study also shows the association between this gene and intelligence in SSD. This 
selective impact of NRN1 on intelligence in SSD may suggest its involvement in 
processes underlying cognitive functioning, which are described to be more 
quantitatively impaired in SSD (Hill et al. 2013). Again, although results did not reach 
significance after permutation, it is of potential interest that the haplotypes identified in 
the present study contain the same haplotype that Chandler et al. (2010) described to be 
associated with better fluid intelligence in schizophrenia patients and not in healthy 
subjects (SNP10-SNP11: C-A).  
In all, our results suggest in a convergent manner that allelic variants in Block 3 of 
NRN1 could represent a protective factor, not only due to their association to a reduction 
of the risk for SSD and BPD, but also because within patients, these variants are related 
to a later of age at onset and a better cognitive performance. This lends support to the 
notion that specific genetic variability could play a role in defining illness subgroups 
and points towards the interest of understanding the pathways from genotype to clinical 
phenotype, which will be crucial for new classification systems and to develop novel 
therapeutic strategies.  
 
In further interpreting these results, it is necessary to consider the results obtained by 
whole genome approaches. To our knowledge, NRN1 has not appeared as a significant 
locus in the published GWAS for schizophrenia and other related disorders. However, 
these negative results could be influenced, for example, by the small effect attributable 
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to common variants or by heterogeneity of the samples. It should also be considered that 
NRN1 could be exerting its effect by means of modifying a more specific trait 
associated with psychotic disorders. In this regard, a genome-wide scan for intelligence 
conducted in a general population sample revealed suggestive linkage for IQ on 6p25.3-
21.31 and already highlighted NRN1 as a positional candidate gene (Posthuma et al. 
2005). Moreover, a subtype of schizophrenia characterized by pervasive cognitive 
deficit was also linked to 6p25-p22 region (Hallmayer et al. 2005). More recently, a 
GWAS has established that common variants (SNPs) may account for 40-50% of 
intelligence variance (Davies et al. 2011) and in a GWAS-based pathway analysis has 
reported that general fluid intelligence appears to be characterized by genes affecting 
quantity and quality of neurons and therefore neuronal efficiency (Christoforou et al. 
2014). Among the genes included in the top pathways identified in this study, there was 
the BDNF, a regulator of NRN1 expression. According to all these data and given the 
described gradual increase in heritability of IQ from childhood to late adolescence 
(Deary et al. 2009; Bouchard 2013) and the reported early occurrence of intellectual 
impairment even years before the onset of the psychotic symptoms (Cannon et al. 
2002), it is plausible that those genes that influence brain development, as NRN1, may 
be modulating illness traits, as IQ and age at onset, and ultimately influencing the risk 
for these disorders.  
 
Although the connection between the NRN1 sequence variability and the risk for SSD 
and BPD is still unclear, the consideration of the putative effects of the analysed 
polymorphic sites on gene expression regulatory mechanisms represents a valuable 
resource to provide additional meaning and importance to our association data. Recent 
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data has revealed the importance of intronic and intergenic variants as regulatory 
elements of gene expression (Dunham et al. 2012). The impact of non-coding variants 
of the NRN1 SNPs can be considered using HaploReg (Ward and Kellis 2012), which is 
a tool that uses LD information from the 1000 Genomes Project to provide data on the 
predicted chromatin state of the queried SNPs, their sequence conservation mammals, 
and their effect on regulatory motifs. As an example, SNP2 (rs12333117), associated 
with age at onset in the present study, is located in a downstream region, in a DNAse 
region (T-47D) and it is predicted to alter several motifs that overlap the recognition 
sequences of transcription factors such as AP-1/Jun, suggesting possible factor-factor 
interactions. There is also evidence that this SNP could modify the promoter histone 
mark H1, which plays an active role in the formation of epigenetic silencing marks 
(Yang et al. 2013). Another example refers to the SNP4 (rs645649), included in the 
identified risk haplotype and that is located in an intronic region where two proteins 
bound: SUZ12 (involved in methylation processes leading to transcriptional repression 
of the affected target genes) and ZNF263 (implicated in basic cellular processes as a 
transcriptional repressor). Furthermore, several resources provide information about the 
correlation between genotype and tissue-specific gene expression levels, which may 
help in the interpretation of molecular genetics association studies (GTEx Project, 
www.gtexportal.org (Lonsdale et al. 2013); BrainCloud, http://braincloud.jhmi.edu/ 
(Colantuoni et al. 2011)). In this regard, variations in NRN1 expression have been 
associated with SNPs along the gene. Therefore, although functional studies are needed, 
the association of NRN1 sequence variants with SSD and BPD phenotypes could be 
linked to the final availability or functionality of the protein which, in turn, could 
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dysregulate NRN1 role on neurite outgrowth and arborization and/or on neuronal 
processes associated with plasticity. 
 
Finally, based on the analyses of epistasis between NRN1 and BDNF, our data suggest 
that the interaction between the Val/Val genotype (BDNF) and the TG genotype (NRN1, 
SNP9: rs9379002) could modulate the risk for SSD and BPD. Despite the fact that 
evidence of a statistical interaction as we report here does not necessarily map directly 
onto biological interaction, it is of note that it is based on a previously described effects 
of BDNF on NRN1 regulation (Naeve et al. 1997). Then, it could be hypothesised that 
the reported functional effects of the BDNF Val66Met polymorphism could impact on 
NRN1 availability or function, explaining therefore the gene-gene interaction on the risk 
for developing SSD and BPD and contributing to understand the controversial results 
associated to single gene analyses. To this respect, some studies have implicated the 
BDNF Val allele in these disorders and, as the Val allele is associated with increased 
synaptic plasticity and growth (Egan et al. 2003), it has been suggested that this allele 
could promote increased synaptic connections between certain brain regions that 
underpin common symptoms. However, recent meta-analyses have failed to confirm the 
direct association of Val66Met polymorphism with the risk for schizophrenia (Zhao et 
al. 2015) or bipolar disorder (Gonzalez-Castro et al. 2014). On the other hand, taking 
into account that BDNF exerts a direct impact on neuronal growth and plasticity in the 
limbic system (Conner et al. 1997; Rattiner et al. 2004), it is of note that G allele 
carriers of rs9379002 (SNP9, NRN1) show higher NRN1 expression than TT 
homozygotes in the hypothalamus (GTEx Project). Then, we could speculate that higher 
expression of both BDNF and NRN1 could be underlying the detected epistatic risk 
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effect. To this respect, it is remarkable that a case-report study suggested the 
relationship between a duplication of NRN1 gene (i.e. increased gene dosage) and the 
white matter and neurocognitive abnormalities observed in one patient (Linhares et al. 
2015). Accordingly, we would have expected to detect the association not only with the 
heterozygous TG genotype but also with the GG. This lack of significant interaction 
could be explained by the low frequency of GG genotype (7%) and the corresponding 
low frequency of the combination of Val/Val x GG (BDNFxNRN1SNP9). Therefore, 
although further studies are needed, these results are in line with recent trends in the 
field of molecular genetics, which consider the importance of testing gene networks 
rather than isolated gene effects for better understanding the gene-phenotype 
relationship in complex disorders (Gilman et al. 2012).  Nonetheless, the fact that the 
SNP9 is included in the protective haplotype while it is detected to exert a risk effect 
when interacts with Val/Val genotype could suggest that the effect of this SNP may 
differ depending on the genetic background in which the alleles are present (Moore 
2003). Moreover, beyond gene-gene interactions, the effect of environmental factors 
should also be considered. In this regard, the fact that NRN1 is classified as an 
immediate early gene (IEG) (Loebrich and Nedivi 2009), meaning that it can be rapidly 
induced by extracellular stimuli and act as a transcription factor on downstream targets, 
highlights the interest of analysing the combined effect of NRN1 and BDNF in gene-
environment studies.  
 
Some limitations of this study must be acknowledged. First, the controls’ age range is 
partially overlapped with the age range of incidence of SSD and BPD. However, due to 
the fact that personal psychiatric history and treatment was discarded, the percentage of 
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false negatives would be very low and should not interfere with the obtained results. 
Second, the polygenic nature of mental disorders and the minor effect of the common 
genetic variants limit the power of our sample size, especially in the case of the analyses 
split by diagnosis. In line with this, although the use of features with strong etiological 
significance has been suggested as a useful strategy to increase the power to detect 
genetic effects, the power of the analyses targeting age at onset and neurocognition is 
reduced due to the non-availability of data in all subjects. This statistical power 
reduction could be related with the loss of significant effects after permutation 
procedures. Third, the antipsychotic treatment was not specified and, therefore, 
cognitive analyses, although covaried by age at onset and months of evolution, were not 
adjusted by treatment type or duration. Fourth, in spite of the interest of the selected 
polymorphism at BDNF due to its functional effects, future studies should include other 
genetic variants along this gene. Lastly, although the permutation procedures have been 
applied, if multiple testing is addressed for the overall analyses not all the findings 
would remain significant. Then, although results cannot be dismissed completely, since 
they come from a directed hypothesis and they are partially in line with a previous study 
(Chandler et al. 2010), their interpretation should be conducted with caution and 
replication studies are needed.  
 
Overall, our results contribute, from a biological approach, to the understanding of the 
genetic mechanisms involved in SSD and BPD and also of the relationship between 
genetic variability and the clinical heterogeneity of these disorders. Then, our findings 
suggest the role of Neuritin 1 gene as a mixed susceptibility/modifier gene (Fanous and 
Kendler 2008), which increases the susceptibility to these disorders and modifies certain 
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presentations. However, new studies should be developed to further acknowledge the 
involvement of NRN1 and its interaction with other genes in the aetiology of these 
mental disorders.  
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Table 1. SNPs genotyped in Neuritin 1 gene (NRN1, chromosome 6p25.1, from 598233 
to 6007633 bp). The table includes the dbSNP number, the genomic and gene position 
and the alleles of the 11 SNPs genotyped along the gene (UCSC Genome Browser on 
Human Mar. 2006 Assembly (hg18), http://genome.ucsc.edu/cgi-bin/hgTracks). 
a
The 
less frequent allele (minor allele) is placed second.  
b
MAF refers to Minor Allele 
Frequency observed in the 1000 Genomes project (Abecasis et al. 2012). 
 
  
 SNP Chr  Position Region Distance from SNP1 Distance from previous SNP Allelesa MAFb 
SNP1 rs2208870 6 5992490 Intergenic   A/G 0.333 
SNP2 rs12333117 6 5994992 Downstream 2502 2502 C/T 0.402 
SNP3 rs582186 6 6001381 Intronic 8891 6389 A/G 0.393 
SNP4 rs645649 6 6004959 Intronic 12469 3578 C/G 0.356 
SNP5 rs582262 6 6007991 Upstream 15501 3032 G/C 0.273 
SNP6 rs3763180 6 6009848 Upstream 17358 1857 G/T 0.437 
SNP7 rs10484320 6 6010437 Upstream 17947 589 C/T 0.236 
SNP8 rs4960155 6 6010539 Upstream 18049 102 T/C 0.492 
SNP9 rs9379002 6 6012391 Intergenic 19901 1852 T/G 0.27 
SNP10 rs9405890 6 6012721 Intergenic 20231 330 T/C 0.309 
SNP11 rs1475157 6 6017169 Intergenic 24679 4448 A/G 0.176 
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Table 2. Sample description and statistical comparisons between patients and controls. 
Proportion (%) or mean scores (standard deviation) are given. (SSD: schizophrenia-spectrum 
disorders, BPD: bipolar disorders) 
 
All Patients 
(n=954) 
SSD 
(n=697) 
BPD 
(n=257) 
Controls 
(n=668) 
Male (%) 65.6 % 71.2 % 50.6 % 46.7 %
*
 
Age at interview  32.33 (13.10) 31.79 (12.83)
  33.9 (13.71) 27.05 (9.99)
*
 
Years of education 10.13 (4.06) 9.58 (3.82) 11.98 (4.29) 13.87(2.87)
*
 
Age at onset 21.54 (6.47)
a,b
 20.72 (5.33)
a
 23.88(8.53)
a, - 
Months of evolution  146.24 (137.6) 140.35 (140.07) 162.93 (129.25) - 
Current IQ  89.80 (15.26)
c
 89.02 (15.37)
c
 92.86 (14.48)
c,  99.48 (13.64)
c*
 
(a) Information about age at onset was available for the 73.5% of patients (74.3% SSD and 71.2% BPD).  
(b) 35.29% were classified as early-onset (first psychotic episode occurred before 18 years of age). 
(c) Information about IQ was available for 63.6% of patients (69.4% SSD and 47.8% BPD) and 71.25% 
of healthy subjects. 
(*) Controls differed significantly from patients (p<0.001) 
(+) BPD patients differed significantly from SSD patients (p<0.03) 
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Table 3. NRN1 most significant haplotypes associated to the risk for schizophrenia-
spectrum and bipolar disorders. Frequency estimates in patients and controls, 
significance levels and OR of the case-control comparison are given. 
SNP1 
 
SNP2 
rs2208870 
 
rs12333117 
G 
I 
C 
   
   
SNP3 rs582186     
SNP4 rs645649  C 
I 
C 
  
SNP5 rs582262   
SNP6 rs3763180   T 
I 
C 
I 
C 
I 
T 
I 
C 
I 
A 
 
SNP7 rs1048432   
SNP8 rs4960155   
SNP9 rs9379002   
SNP10 rs9405890   
SNP11 rs1475157   
Ca- Freq 
a
 34.3 25.9 0.1  
Co- Freq 
b
 30.7 21.4 1.5  
χ2 
OR (CI 95%) 
c 
4.26 
1.18 
(1.01-1.37) 
7.99 
1.28 
(1.08-1.51) 
17.45 
0.09 
(0.02-0.37) 
 
Global p- value 0.11 0.038 0.001  
Individual haplotype p - value  0.037ǂ 0.0043* 0.000031**  
a  
Ca - Freq refers to each haplotype frequency within  cases 
b 
 Co - Freq refers to  each haplotype frequency within controls  
c
   Chi-squared tests  and Odds ratio (OR) were estimated from the absolute number of observed haplotypes in 
cases and controls  
ǂ
 No significant after performing 10000 permutations, adjusted p value from permutation test p = 0.1748 
* Significant adjusted level based on 10000 permutations,  adjusted p value from permutation test p = 0.0219 
** Significant adjusted level based on 10000 permutations,  adjusted p value from permutation test  p = 0.002 
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Figure 1. Relationship between NRN1 and age at onset and IQ in SSD patients. 
Linear regression graphs showing the relationship between SSD patients’ NRN1 
haplotypes and: (A) age at onset, (B) IQ. For illustration purposes, the haplotype dump 
option was used to estimate individual haplotype phases. Considering only those 
haplotypes estimated with a probability 95%, each subject was defined according to its 
haplotype dose. A) The most significant NRN1 haplotype associated to age at onset 
(SNP10-11: C-A, =0.89 p=0.019) was selected and SSD patients were classified as:  
47.01% non-carriers (0), 45.41% one-copy carriers (1) and 7.58% two-copy carriers (2). 
B) The haplotype C-T-G-C-A (SNP7-11) was selected to represent graphically the 
detected association between NRN1 variability and IQ within SSD patients (=4.02 
p=0.022). Patients were classified as: 82.2% non-carriers (0), 16.9% one-copy carriers 
(1) and 0.9% two-copy carriers (2).  
 
 
 
 
 
